Rafael_Pharma-Logo+Slogan.png
Rafael Pharmaceuticals Joins the Pancreatic Cancer Action Network’s Scientific & Medical Affairs Industry Membership
November 07, 2019 09:00 ET | Rafael Pharmaceuticals, Inc.
Cranbury, NJ, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today that...
Rafael_Pharma-Logo+Slogan.png
Rafael Pharmaceuticals Appoints Chief Medical Officer, José Octávio Costa Filho, M.D.
October 30, 2019 09:00 ET | Rafael Pharmaceuticals, Inc.
Cranbury, NJ, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced that...
Rafael_Pharma-Logo+Slogan.png
Rafael Pharmaceuticals Appoints Wendy McDermott to Chief People Officer
October 02, 2019 09:00 ET | Rafael Pharmaceutical Inc.
Newark, NJ, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced the...
Rafael_Pharma-Logo+Slogan.png
Rafael Pharmaceuticals Announces Expansion into South Korea of Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (devimistat) in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
September 19, 2019 09:00 ET | Rafael Pharmaceutical Inc.
CRANBURY, N.J., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced...
Rafael_Pharma-Logo+Slogan.png
Rafael Pharmaceuticals Launches Clinical Trial Web Portal “Rafael Trial Connect”
August 05, 2019 09:00 ET | Rafael Pharmaceutical Inc.
Newark, NJ, Aug. 05, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today the...
Rafael_Pharma-Logo+Slogan.png
Rafael Pharmaceuticals Enters into Out-Licensing Agreement with Ono Pharmaceutical to Accelerate Clinical Development and Commercialization of Cancer Drug Candidate CPI-613® (devimistat) in Japan and Other Asian Countries
June 25, 2019 08:00 ET | Rafael Pharmaceutical Inc.
Cranbury, NJ, June 25, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today that...